<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01518699</url>
  </required_header>
  <id_info>
    <org_study_id>Ha02-005</org_study_id>
    <nct_id>NCT01518699</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Male and Female Adult Subjects, Preceded by a Dose-Escalation Study to Determine the Supratherapeutic Dose of Ha44</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hatchtech Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hatchtech Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in
      Healthy Volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: safety and tolerability of single applications of Ha44</measure>
    <time_frame>6 months</time_frame>
    <description>safety and tolerability of single applications of Ha44 of increasing exposure duration assessed by the following measures: AEs, application site reactions, blood pressure and other vital sign measurements, 12 lead ECGs, incidence and magnitude of clinically significant changes from baseline in clinical laboratory values (hematology, chemistry, and urinalysis), and physical examinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: difference between the post-dose time matched baseline adjusted mean QTcF (Ha44 0.74% Gel) and the post dose time-matched baseline adjusted mean QTcF (placebo)</measure>
    <time_frame>6 months</time_frame>
    <description>The primary endpoint for Part 2 is the difference between the post-dose time matched baseline adjusted mean QTcF (Ha44 0.74% Gel) and the post dose time-matched baseline adjusted mean QTcF (placebo) = [ΔQTcF (Ha44 0.74% Gel) - ΔQTcF (placebo)] = ΔΔQTcF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: PK parameters</measure>
    <time_frame>6 months</time_frame>
    <description>PK parameters: Cmax, Tmax area under the curve from time zero to the last quantifiable sample AUClast) and also extrapolated to infinity (AUCinf), and the terminal-phase rate constant and half life (t½).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: The effect of Ha44 0.74% Gel compared to placebo on cardiac parameters</measure>
    <time_frame>6 months</time_frame>
    <description>Part 2: The effect of Ha44 0.74% Gel compared to placebo on QTcB, heart rate, PR interval, RR interval, QRS interval, uncorrected QT interval, change in ST and T-wave morphology, categorical change in QTc variables, and correlation between the QTcF change from baseline and plasma concentrations.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Pediculosis</condition>
  <arm_group>
    <arm_group_label>Part 1 Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Low dose study drug in 6 of 8 subjects Placebo in 2 of 8 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Mid dose study drug in 6 of 8 subjects Placebo in 2 of 8 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Group 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>High dose study drug in 6 or 8 subjects Placebo in 2 of 8 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Group A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study drug plus positive-control placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Group B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo plus positive-control placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Group C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo plus positive control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ha44</intervention_name>
    <description>study drug at low, moderate and high dose single exposure</description>
    <arm_group_label>Part 1 Group 1</arm_group_label>
    <arm_group_label>Part 1 Group 2</arm_group_label>
    <arm_group_label>Part 1 Group 3</arm_group_label>
    <arm_group_label>Part 2 Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ha44 Placebo</intervention_name>
    <description>Ha44 Vehicle Gel without Ha44</description>
    <arm_group_label>Part 1 Group 1</arm_group_label>
    <arm_group_label>Part 1 Group 2</arm_group_label>
    <arm_group_label>Part 1 Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin Placebo</intervention_name>
    <description>Moxifloxacin Placebo</description>
    <arm_group_label>Part 2 Group A</arm_group_label>
    <arm_group_label>Part 2 Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>moxifloxacin 400mg</description>
    <arm_group_label>Part 2 Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male or female subject, 18 to 50 years of age, inclusive, at least 45 kg and
             has a body mass index (BMI) of 18 to 33 kg/m2,

          -  Female subjects of childbearing potential must not be pregnant and not lactating or
             prepared to practice highly effective birth control methods

          -  The subject has normal 12-lead ECG results or, if abnormal, the abnormality is not
             clinically significant (as determined by the investigator).

        Exclusion Criteria:

          -  has evidence of cardiac conduction abnormalities

          -  history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmia or
             torsade de pointes, structural heart disease, or family history of Long QT syndrome
             (suggested by sudden death of a close relative due to cardiac causes at a young age

          -  potassium, calcium, or magnesium levels that are below the clinical laboratory's lower
             limit of normal

          -  laboratory test results at Screening are &gt;2 x the upper limit of normal (ULN) for
             alanine aminotransferase (ALT) or aspartate aminotransferase (AST), &gt;1.5 x ULN for
             bilirubin, or &gt;1.5 x ULN for creatinine

          -  history or evidence of any clinically significant (as determined by the investigator)
             cardiovascular, endocrinologic, hematologic, hepatic, immunologic, metabolic,
             urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major
             disease or malignancy (excluding non-melanoma skin cancer)

          -  febrile illness or symptomatic viral, bacterial (including upper respiratory
             infection), or fungal (non-cutaneous) infection within 1 week before clinic admission

          -  supine mean systolic blood pressure &lt;90 or &gt;140 mmHg and a mean diastolic blood
             pressure &lt;50 or &gt;90 mmHg

          -  positive for HIV or hepatitis C antibody or hepatitis B antigen (HBsAg)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Dietz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spaulding Clinical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spaulding Clinical</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2012</study_first_submitted>
  <study_first_submitted_qc>January 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2012</study_first_posted>
  <last_update_submitted>July 22, 2013</last_update_submitted>
  <last_update_submitted_qc>July 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lice Infestations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

